AUTHORS
Guillermo Garcia-Manero, MD, Uma Borate, MBBS, MSc2, Amer M. Zeidan, MD3, James K. McCloskey, MD4, Bart L Scott, MD5, Andrew M Brunner, MD6, Agnieszka Wierzbowska, MD, PhD7, Raquel De Paz Arias, MD8, Marina Díaz-Beyá9, Gabriela Rodriguez-Macias, MD, PhD10, Austin G. Kulasekararaj, MD, MBBS, FRCPath, MRCP11, Yuri Sano, MD, PhD12, Danna Chan, MSc, PharmD13, Lixia Zhu14, Aram Oganesian, PhD15, Harold Keer, MD, PhD16, Elizabeth A Griffiths, MD17, Michael R. Savona, MD18
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
3 Yale School of Medicine - Yale Cancer Center, New Haven, Connecticut, United States
4 Hackensack University Medical Center, Hackensack, New Jersey, United States
5 Fred Hutchinson Cancer Center, Seattle, Washington, United States
6 Dana-Farber Cancer Institute, Boston, Massachusetts, United States
7 Department of Hematology, Medical University of Lódz, Lódz, Poland, Provincial Multi-Specialty Center of Oncology and Traumatology, Lódz, Poland
8 La Paz University Hospital, Madrid, Spain
9 Hospital Clínic de Barcelona, Barcelona, Spain
10 Hospital General Universitario Gregorio Marañon, Instituto de Investigacio´n Sanitaria Gregorio Maran~o´n (IiSGM), Madrid, Spain
11 King's College Hospital NHS Foundation Trust - King's College Hospital, London, United Kingdom
12 Taiho Oncology, Inc, Princeton, New Jersey, United States
13 Taiho Oncology, Inc, Princeton, New Jersey, United States
14 Taiho Oncology, Inc, Princeton, New Jersey, United States
15 Taiho Oncology, Inc, Princeton, New Jersey, United States
16 Taiho Oncology, Inc, Princeton, New Jersey, United States
17 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
18 Vanderbilt University School of Medicine, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
ABSTRACT
INTRODUCTION: Parenteral azacitidine (AZA) and decitabine (DEC) are standard treatments for MDS and AML. Oral formulations are less invasive and time-consuming and are often preferred by patients. Cedazuridine (CED) enhances oral bioavailability of cytidine analogues like AZA and DEC. Oral DEC plus CED (35 mg/100 mg) was approved in the United States in 2020 to treat MDS and chronic myelomonocytic leukemia (CMML) by demonstration of PK-exposure equivalence. In 2026, oral DEC plus CED was approved in combination with venetoclax for newly diagnosed AML. AZA tablets are approved as maintenance therapy for certain patients with AML. However, oral AZA alone does not provide the same exposure levels of the parenteral route. ASTX030 is an oral combination of AZA and CED under investigation in the phase 1–3 ASTX030-01 trial (AZTOUND; NCT04256317). Preliminary data presented for phase 1 and 2 suggest a recommended phase 2 dose (RP2D) of 140 mg AZA/20 mg CED best matches the PK exposure following subcutaneous (SC) AZA administration and that using dosing based on body surface area (BSA) more closely matches the exposure. Here we present the phase 3 PK results and more mature pooled phase 1/2 efficacy results at the relevant doses.
METHODS: ASTX030-01 comprised 3 phases. The open-label, phase 1, dose-finding study was to determine the ASTX030 RP2D; the multicenter, randomized, open-label, crossover, phase 2 study compared AZA PK exposure after oral ASTX030 and SC AZA during the crossover treatment, with ASTX030 monotherapy thereafter, in patients with confirmed MDS, CMML, other MDS/MPNs, or AML. The pooled efficacy analysis included patients with MDS from phases 1 and 2 treated with ASTX030 at approximate RP2D levels in phase 1 (136 mg/20 mg, 140 mg/20 mg, and 144 mg/20 mg) and at the RP2D in phase 2 (140 mg/20 mg). Efficacy endpoints included overall response (OR; complete response [CR] + partial response [PR] + marrow CR + hematologic improvement per IWG 2006 criteria) and overall survival (OS). The ongoing randomized, crossover phase 3 part of the trial is evaluating AZA exposure following oral ASTX030 and SC AZA in patients with MDS or CMML. ASTX030 is dosed based on BSA to provide optimal AZA exposure across the patient population (105 mg/20 mg, 140 mg/20 mg, and 175 mg/20 mg, respectively, for low-, intermediate-, and high-BSA groups). The primary objective is to establish AZA area under the curve (AUC0-24) equivalence (90% CI 0.8, 1.25) between ASTX030 and SC AZA 75 mg/m2/day. Safety and changes in DNA methylation were secondary objectives.
RESULTS: At the March 13, 2026 data cutoff, the pooled phase 1/2 MDS population (n=45) had a median age of 73 years. Patients were treated at/near RP2D and received a median of 6 treatment cycles; median duration of treatment was 5.7 months. Median duration of follow-up (range) for the pooled MDS population was 25.6 months (19–33). OR was achieved in 20/45 patients had an OR (44.4%, 95% CI 29.6, 60.0); 9 patients (20.0%) had a CR per International Working Group 2006 response criteria. Median OS (95% CI) for the pooled MDS population was not reached (21.6, not evaluable). For the phase 3 analysis, the AUC equivalence analysis was conducted with 83 patients in the primary PK population. Geometric mean ratio for the primary PK endpoint was 95.2% (90% CI 86.5–104.7), indicating that the trial met its primary endpoint. Oral ASTX030 and SC AZA had similar demethylation profiles based on percent long interspersed nuclear elements-1 (LINE-1) demethylation from baseline. Safety was summarized using the January 15, 2026 data cutoff, and included 71 patients. Median duration of treatment was 1.60 months. Safety findings from phase 3 were consistent with the known AZA safety profile. Treatment-emergent adverse events (TEAEs) were reported in 92% of patients, with 68% experiencing grade ≥3 TEAEs. The most common grade ≥3 TEAEs were anemia (24%) and neutropenia (20%). Serious AEs occurred in 34% of patients, most commonly febrile neutropenia (9%) and pneumonia (6%). No new safety signals were identified.
CONCLUSIONS: Oral ASTX030 showed efficacy in patients with MDS in pooled phase 1/2 analyses. The phase 3 trial met its primary objective of confirming AUC equivalence of oral ASTX030 with SC AZA. Other phase 3 trial objectives, including clinical activity, will be assessed as the study continues but are expected to mirror the more mature efficacy seen in the pooled phase 1/2 analyses.
DISCLOSURES
Guillermo Garcia-Manero, MD: Abbvie - Research Funding; Novartis - Research Funding; Rigel - Research Funding; GSK - Research Funding; Curis - Research Funding; BMS - Research Funding; Chordia - Research Funding; AstraZeneca - Research Funding; Genentech - Research Funding; Zentalis - Research Funding; Taiho - Research Funding; Ascentage - Research Funding; Servier - Research Funding; Takeda - Research Funding; BMS - Patents & Royalties